Latest total current liabilities for AUPH: $100M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Aurinia Pharmaceuticals (AUPH) currently reports a total current liabilities of $100M as of June 2026. That compares with $78M in the prior-year period — up 27.6% year over year. Use the charts on this page to explore Aurinia Pharmaceuticals's total current liabilities history and peer comparisons.
Aurinia Pharmaceuticals's total current liabilities increased from $78M to $100M — a 27.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Aurinia Pharmaceuticals reported $100M in total current liabilities as of June 2026. That compares with $78M in the prior-year period — up 27.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aurinia Pharmaceuticals, and consider following AUPH for alerts when major investors trade the stock.
Aurinia Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $100M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AUPH with unrelated industries.